Medicare Enrolled
Dr. Naveed Khan, MD
Medical Oncology · Glendora, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khan
Dr. Naveed Khan is a medical oncology specialist in Glendora, CA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Khan performed 10,632 Medicare services across 915 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khan received a total of $2,891 from 34 pharmaceutical and/or device companies across 135 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 19% volume in CA
$2,891 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,632
Medicare services
Top 19% in CA for medical oncology
915
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~625 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 3,640 | $1 | $6 |
| Denosumab injection (Prolia/Xgeva) | 3,600 | $18 | $82 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,178 | $66 | $256 |
| Anti-nausea injection (ondansetron/Zofran) | 656 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
506 | $0 | $0 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
248 | $68 | $339 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
169 | $144 | $644 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
100 | $100 | $476 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
96 | $14 | $93 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
86 | $12 | $81 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
73 | $119 | $606 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
41 | $63 | $228 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
36 | $41 | $216 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
31 | $59 | $269 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
31 | $26 | $147 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
29 | $59 | $295 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
26 | $25 | $134 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
26 | $32 | $180 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
21 | $153 | $663 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
21 | $100 | $389 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
18 | $18 | $84 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.7% high complexity
81.0% medium
17.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,891
Total received (2018-2024)
Avg $413/year across 7 years
Bottom 43% in CA for medical oncology
34
Companies
135
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,494 (86.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$397 (13.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,252
2023
$455
2022
$165
2021
$358
2020
$299
2019
$313
2018
$49
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$217
Merck Sharp & Dohme LLC
$145
AstraZeneca Pharmaceuticals LP
$144
Janssen Biotech, Inc.
$99
Gilead Sciences, Inc.
$59
Tempus AI, Inc
$59
Boston Scientific Corporation
$54
EMD Serono, Inc.
$54
Karyopharm Therapeutics Inc.
$49
Aveo Pharmaceuticals, Inc.
$36
Amgen Inc.
$32
Daiichi Sankyo Inc.
$30
Lilly USA, LLC
$29
Takeda Pharmaceuticals U.S.A., Inc.
$29
Celgene Corporation
$28
ADC Therapeutics America, Inc.
$26
ABBVIE INC.
$25
PFIZER INC.
$23
Janssen Pharmaceuticals, Inc
$22
Bayer Healthcare Pharmaceuticals Inc.
$22
Eisai Inc.
$21
GENZYME CORPORATION
$18
Astellas Pharma US Inc
$18
E.R. Squibb & Sons, L.L.C.
$15
Top 3 companies account for 40.4% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$313
AstraZeneca Pharmaceuticals LP
$246
Amgen Inc.
$246
PFIZER INC.
$241
Janssen Biotech, Inc.
$173
Gilead Sciences, Inc.
$168
E.R. Squibb & Sons, L.L.C.
$166
Merck Sharp & Dohme LLC
$164
Astellas Pharma US Inc
$87
Karyopharm Therapeutics Inc.
$81
Celgene Corporation
$78
PUMA BIOTECHNOLOGY, INC.
$73
Genentech USA, Inc.
$71
Incyte Corporation
$68
Tempus AI, Inc
$59
Bayer Healthcare Pharmaceuticals Inc.
$55
Lilly USA, LLC
$55
Boston Scientific Corporation
$54
EMD Serono, Inc.
$54
GlaxoSmithKline, LLC.
$53
Merck Sharp & Dohme Corporation
$40
Mirati Therapeutics, Inc.
$39
Bayer HealthCare Pharmaceuticals Inc.
$37
Aveo Pharmaceuticals, Inc.
$36
Daiichi Sankyo Inc.
$30
Takeda Pharmaceuticals U.S.A., Inc.
$29
ADC Therapeutics America, Inc.
$26
ABBVIE INC.
$25
Seagen Inc.
$24
Pharmacyclics LLC, An AbbVie Company
$22
Janssen Pharmaceuticals, Inc
$22
Eisai Inc.
$21
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
GENZYME CORPORATION
$18
Top 3 companies account for 27.8% of all-time payments
Associated products mentioned in payments ›
BLENREP · BOSULIF · BRAFTOVI · Blincyto · DARZALEX · ELAHERE · ENHERTU · ERLEADA · EVENITY · Enhertu · FOTIVDA · Fabhalta · GILOTRIF · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LORBRENA · Lenvima · MEKINIST · MONJUVI · NERLYNX · Nplate · Nubeqa · OJJAARA · OPDIVO · PIQRAY · PROMACTA · Perjeta · Pomalyst · Revlimid · SARCLISA · SCEMBLIX · Stivarga · TAGRISSO · TECENTRIQ · TUKYSA · TheraSphere Y90 Glass Microspheres 10 GBq · Trodelvy · VERZENIO · Venclexta · XGEVA · XPOVIO · XTANDI · Xospata
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
48
Per 100K population
0.5
County median income
$87,760
Nearest hospital
EMANATE HEALTH FOOTHILL PRESBYTERIAN HOSPITAL
3.3 mi
3.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Khan is a mixed practice specialist, with above-average Medicare volume (top 19% in CA), with low-engagement industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Khan experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Khan performed 3,640 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khan receive payments from pharmaceutical companies?
Yes. Dr. Khan received a total of $2,891 from 34 companies across 135 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khan's costs compare to other medical oncologists in Glendora?
Dr. Khan's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Glendora
Browse medical oncologists in Glendora ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology